Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus
- 16 February 2004
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 202 (3), 313-320
- https://doi.org/10.1002/path.1520
Abstract
Vascular endothelial growth factor (VEGF)-A is an important angiogenic factor in establishing the vasculature in renal cell carcinomas (RCCs). Since little is known about VEGF signalling in RCCs, the profile of phosphorylated KDR (pKDR) has been investigated and the intracellular location of the receptor has been examined in the present study. Using two monoclonal antibodies raised against the phosphorylated KDR epitopes (Y1059 and Y1214) known to mediate different VEGF functions, together with a commercial anti-KDR antibody and immunohistochemistry, the expression of pKDR was investigated in a series of normal (n = 25) and neoplastic kidneys (n = 54; clear cell n = 35; papillary n = 10; oncocytomas n = 8). pKDR was present in many tissue elements of both normal and neoplastic renal tissues, with strong expression in the cell membrane, cytoplasm, and nuclei of normal kidney and tumour cells, as well as endothelial cells in tumours of all histological types. Patterns and intensity were similar using both anti-pKDR antibodies. There was no significant correlation in clear cell carcinomas between pKDR expression and age (p = 0.57), tumour size (p = 0.2), gender (p = 0.59), grade (p = 0.2) or histological type (p = 0.36). To delineate further the intracellular processing that might account for the cellular distribution, confocal microscopy was also performed. Antibodies to the different phosphorylated epitopes demonstrated different intracellular staining patterns. This study shows that pKDR is present in a wide variety of renal tumours, suggesting that anti-VEGF therapy might have direct effects on tumour cells. It further suggests that cells traffic pKDR depending on the precise KDR tyrosines that are autophosphorylated in a manner that enables receptor activation to result in different functions. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 35 references indexed in Scilit:
- Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel‐Lindau gene and hypoxiaThe Journal of Pathology, 2002
- Vasculogenic Mimicry and Tumor AngiogenesisThe American Journal of Pathology, 2000
- Role of vascular endothelial growth factor in the regulation of angiogenesisKidney International, 1999
- Vascular endothelial growth factor platelet counts, and prognosis in renal cancerThe Lancet, 1999
- VEGF Induces Nuclear Translocation of Flk-1/KDR, Endothelial Nitric Oxide Synthase, and Caveolin-1 in Vascular Endothelial CellsBiochemical and Biophysical Research Communications, 1999
- VEGF145, a Secreted Vascular Endothelial Growth Factor Isoform That Binds to Extracellular MatrixPublished by Elsevier BV ,1997
- Enhancement of Tumor Growth and Vascular Density by Transfection of Vascular Endothelial Cell Growth Factor Into MCF-7 Human Breast Carcinoma CellsJNCI Journal of the National Cancer Institute, 1995
- Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factorBiochemical and Biophysical Research Communications, 1992
- The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth FactorScience, 1992
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989